• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Torisel (temsirolimus)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Torisel (temsirolimus)

  • Profile

Profile

Contact Information

Contact: Wyeth Pharmaceuticals
Website: https://wyethpharma.com/

Currently Enrolling Trials

    Show More

    General Information

    Torisel is a derivative of rapamycin, an agent that exhibits antifungal, immunosuppressant and antitumor activities. Torisel appears to block the effects of mTOR, an enzyme that has an important role in regulating the synthesis of proteins that control cell division. Therefore, Torisel may stop the production of proteins essential for cancer cell proliferation.

    Torisel is specifically indicated for the treatment of advanced renal cell carcinoma.

    Mechanism of Action

    Torisel is a derivative of rapamycin, an agent that exhibits antifungal, immunosuppressant and antitumor activities. Torisel appears to block the effects of mTOR, an enzyme that has an important role in regulating the synthesis of proteins that control cell division. Torisel binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway, was blocked. Therefore, Torisel may stop the production of proteins essential for cancer cell proliferation.

    Side Effects

    Adverse reactions associated with the use of Torisel may include, but are not limited to, the following:

    • Rash
    • Asthenia
    • Mucositis
    • Nausea
    • Edema
    • Anorexia

    Dosing/Administration

    Torisel is supplied as a 25 mg/mL injection with a 1.8 mL diluent designed for injection. The recommended initial dose of the drug is 25 mg infused over a 30 to 60-minute period once a week. Treat until disease progression or unacceptable toxicity. Torisel injection vial contents must first be diluted with the enclosed diluent before diluting the resultant solution with 250 mL of 0.9% sodium chloride injection. Patients should receive prophylactic intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose. The concomitant use of strong CYP3A4 inhibitors should be avoided. If these are co-administered, a Torisel dose reduction to 12.5 mg/week should be considered. If the strong inhibitor is discontinued, a washout period of approximately one week should be allowed before the Torisel dose is adjusted back to the dose used prior to initiation of the strong CYP3A4 inhibitor. In addition, the use of concomitant strong CYP3A4 inducers should be avoided. If these are co-administered, a Torisel dose increase from 25 mg/week up to 50 mg/week should be considered. If the strong inducer is discontinued the Torisel dose should be returned to the dose used prior to initiation of the strong CYP3A4 inducer.

    Clinical Trial Results


    FDA approval of Torisel was based on the results of one clinical trial. This multi-center, three-arm, randomized, open-label study enrolled previously untreated subjects with advanced renal cell carcinoma. Subjects were randomly assigned (1:1:1) to receive IFN-a alone, Torisel alone (25 mg weekly) or the combination arm. The median duration of treatment in the Torisel arm was 17 weeks. The median duration of treatment in the IFN arm was eight weeks. The objectives were to compare Overall Survival (OS), Progression-Free Survival (PFS), Objective Response Rate (ORR) and safety in patients receiving IFN-a to those receiving Torisel or Torisel plus IFN-a. The intent to treat (ITT) population included 626 subjects. There was a statistically significant improvement in OS in the Torisel (25 mg) arm compared to IFN-a. The combination of TORISEL 15 mg and IFN-a did not result in a significant increase in overall survival when compared with IFN-a alone. The median progression free survival in the Torisel arm was 5.5 months compared to 3.1 months in the IFN-a arm and the overall response rate was 8.6% for the Torisel arm compared to 4.8% in the IFN-a arm.

     

    Approval Date: 2007-05-01
    Company Name: Wyeth
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing